未知股票 NOVN 深 沪
已收盘
--
0.000
NaN.00%
华盛通- 最 高--
- 今 开--
- 成交量 --
- 最 低 --
- 昨 收 --
- 总市值 0
- 52周最高 --
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 --
- 委 比 0.00%
- 总股本 2801.54万
- 历史最高 --
- 量 比 0
- 振 幅 NaN.00%
- 历史最低 --
- 每 手 1
- 风险率 0.66%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多FOCUS-Drugmakers delay some European launches with a wary eye on Trump's pricing policies
FOCUS-Drugmakers delay some European launches with a wary eye on Trump's pricing policies Trump most-favored-nation deals cause pricing uncertainty Data shows 35% drop in European new drug launches Companies say they want more clarity on US prices first Situation bolsters US position as first go-to
03-31 14:00
Baird Upgrades Novanta to Outperform, Lowers Price Target to $144
Baird analyst Robert Mason upgrades Novanta (NASDAQ:NOVT) from Neutral to Outperform and lowers the price target from $150 to $144.
03-30 20:54
UPDATE 2-US FDA approves higher dose of Biogen's genetic disorder drug
UPDATE 2-US FDA approves higher dose of Biogen's genetic disorder drug Adds background throughout March 30 (Reuters) - The U.S. Food and Drug Administration has approved a higher-dose version of Biogen's BIIB.O drug for a rare genetic disorder that causes progressive muscle weakness, the company sai
03-30 19:46
Novartis to buy U.S.-based biotech firm Excellergy for up to $2 billion
Novartis to buy U.S.-based biotech firm Excellergy for up to $2 billion March 27 (Reuters) - Swiss pharma company Novartis NOVN.S said on Friday it will acquire California-based biotech company Excellergy in a deal worth up to $2 billion. Under the agreement, Novartis said it would pay up to $2 bill
03-27 14:26
BRIEF-Novartis Agrees To Acquire Excellergy, Inc.
BRIEF-Novartis Agrees To Acquire Excellergy, Inc. March 27 (Reuters) - Novartis AG NOVN.S : NOVARTIS AGREES TO ACQUIRE EXCELLERGY, INC., BUILDING ON ALLERGY LEADERSHIP WITH NEXT-GENERATION ANTI-IGE INNOVATION NOVARTIS AG - TO PAY UP TO $2 BILLION TO BUY EXCELLERGY NOVARTIS AG - NOVARTIS WILL PAY UP
03-27 14:05
UPDATE 2-Merck boosts cancer portfolio with $6.7 billion Terns deal
UPDATE 2-Merck boosts cancer portfolio with $6.7 billion Terns deal Adds background and details from paragraph 4 March 25 (Reuters) - Merck MRK.N said on Wednesday it would buy biotech Terns Pharma TERN.O for $6.7 billion, as the drugmaker races to bolster its cancer pipeline ahead of the looming pa
03-25 18:54
Novartis to buy breast cancer drug candidate from Synnovation
Novartis to buy breast cancer drug candidate from Synnovation FRANKFURT, March 20 (Reuters) - Novartis NOVN.S said on Friday it agreed to acquire breast cancer drug candidate SNV4818 from Synnovation Therapeutics for $2 billion upfront and up to $1 billion contingent on further development achieveme
03-20 14:24
Ethos rejects Novartis CEO, management pay as excessive
Ethos rejects Novartis CEO, management pay as excessive ZURICH, Feb 24 (Reuters) - Proxy advisory firm Ethos on Tuesday urged shareholders of Novartis NOVN.S to reject pay-related items at the pharma company's upcoming annual general meeting, calling the 2025 remuneration for CEO Vasant Narasimhan "
02-24 15:20
Novanta Q4 revenue rises
Novanta Q4 revenue rises Overview Tech partner's Q4 revenue up 9%, beating analyst expectations Adjusted EPS for Q4 beat analyst expectations Adjusted EBITDA for Q4 missed analyst expectations Outlook Novanta expects 2026 GAAP revenue between $1,030 mln and $1,050 mln Company anticipates 2026 Adjust
02-24 05:54
Novanta Sees FY2026 Adj EPS $3.50-$3.65 vs $3.61 Est; Sees Sales $1.030B-$1.050B vs $1.043B Est
Novanta (NASDAQ:NOVT) is looking for FY2026 Adj EPS of $3.50-$3.65 vs $3.61 analyst estimate. sees sales of $1.030 billion-$1.050 billion vs $1.043 billion analyst estimate.
02-24 05:47
